Syringe free vaccination with CAF01 adjuvated Ag85B-ESAT- 6 in bioneedles provides strong and prolonged protection against tuberculosis

PLoS ONE

Volumn 5, Issue 11, 2010, Pages

  Christensen, Dennis ^a   Lindenstrøm, Thomas ^a   van de Wijdeven, Gijsbert ^b   Andersen, Peter ^a   Agger, Else Marie ^a  

^a STATENS SERUM INSTITUT   (Denmark)

^b Bioneedle Technologies Group BV   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL VACCINE; BCG VACCINE; CAF 01 ADJUVANT; CD8 ANTIGEN; GAMMA INTERFERON; H1 VACCINE; HERMES ANTIGEN; IMMUNOLOGICAL ADJUVANT; INTERLEUKIN 2; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; BACTERIAL ANTIGEN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN SPECIFICITY; ARTICLE; BCG VACCINATION; BIONEEDLE; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG DELIVERY SYSTEM; DRUG EFFICACY; FEMALE; IMMUNE RESPONSE; IMMUNOGENICITY; INTERFERON PRODUCTION; LUNG TUBERCULOSIS; LYMPHOCYTE DIFFERENTIATION; MEMORY T LYMPHOCYTE; MOUSE; NEEDLE; NONHUMAN; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; SPLEEN CELL; SYRINGE; VACCINATION; ANALYSIS OF VARIANCE; ANIMAL; CYTOLOGY; FLOW CYTOMETRY; IMMUNOLOGY; INSTRUMENTATION; METABOLISM; METHODOLOGY; MYCOBACTERIUM TUBERCULOSIS; TIME; TUBERCULOSIS;

ANALYSIS OF VARIANCE; ANIMALS; ANTIGENS, BACTERIAL; CD4-POSITIVE T-LYMPHOCYTES; FLOW CYTOMETRY; INTERFERON-GAMMA; MICE; MYCOBACTERIUM TUBERCULOSIS; NEEDLES; SYRINGES; TIME FACTORS; TUBERCULOSIS; TUBERCULOSIS VACCINES; VACCINATION;

EID: 78649758720     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0015043     Document Type: Article

References (21)

1. Salehi AS, Garner P (2010) Occupational injury history and universal precautions awareness: a survey in Kabul hospital staff. BMC Infect Dis 10.
2. Pruss-Ustun A, Rapiti E, Hutin Y (2005) Estimation of the global burden of disease attributable to contaminated sharps injuries among health-care workers. Am J Ind Med 48: 482-490.
3. Hauri AM, Armstrong GL, Hutin YJF (2004) The global burden of disease attributable to contaminated injections given in health care settings. Int J STD & AIDS 15: 7-16.
4. Ishii Y, Nakae T, Sakamoto F, Matsuo K, Matsuo K, et al. (2008) A transcutaneous vaccination system using a hydrogel patch for viral and bacterial infection. J Control Rel 131: 113-120.
5. Kim YC, Quan FS, Yoo DG, Compans RW, Kang SM, et al. (2010) Enhanced memory responses to seasonal H1N1 influenza vaccination of the skin with the use of vaccine-coated microneedles. J Infect Dis 201: 190-198.
6. Prausnitz MR, Mikszta JA, Cormier M, Andrianov AK (2009) Microneedlebased vaccines. Curr Top Microbiol Immunol 333: 369-393.
7. Canter J, Mackey K, Good LS, Roberto RR, Chin J, et al. (1990) An outbreak of hepatitis B associated with jet injections in a weight reduction clinic. Arch Intern Med 150: 1923-1927.
8. Kelly K, Loskutov A, Zehrung D, Puaa K, LaBarre P, et al. (2008) Preventing contamination between injections with multiple-use nozzle needle-free injectors: A safety trial. Vaccine 26: 1344-1352.
9. du Châtelet IP, Lang J, Schlumberger M, Vidor E, Soula G, et al. (1997) Clinical immunogenicity and tolerance studies of liquid vaccines delivered by jet-injector and a new single-use cartridge (ImuleH): comparison with standard syringe injection. Vaccine 15: 449-458.
10. van de Wijdeven GG (2002) Development and assessment of mini projectiles as drug carriers. J Control Rel 85: 145-162.
11. Hirschberg HJ, van de Wijdeven GG, Kelder AB, van den Dobbelsteen GP, Kersten GF (2008) Bioneedles as vaccine carriers. Vaccine 26: 2389-2397.
12. Agger EM, Andersen P (2001) Tuberculosis subunit vaccine development: on the role of interferon-gamma. Vaccine 19: 2298-2302.
13. Agger EM, Rosenkrands I, Hansen J, Brahimi K, Vandahl BS, et al. (2008) Cationic liposomes formulated with synthetic mycobacterial cordfactor (CAF01): a versatile adjuvant for vaccines with different immunological requirements. PLoS ONE 3: e3116.
14. Holten-Andersen L, Doherty TM, Korsholm KS, Andersen P (2004) Combination of the cationic surfactant dimethyl dioctadecyl ammonium bromide and synthetic mycobacterial cord factor as an efficient adjuvant for tuberculosis subunit vaccines. Infect Immun 72: 1608-1617.
15. Lindenstrom T, Agger EM, Korsholm KS, Darrah PA, Aagaard C, et al. (2009) Tuberculosis subunit vaccination provides long-term protective immunity characterized by multifunctional CD4 memory T cells. J Immunol 182: 8047-8055.
16. Seder RA, Darrah PA, Roederer M (2008) T-cell quality in memory and protection: implications for vaccine design. Nat Rev Immunol 8: 247-258.
17. Henriksen-Lacey M, Bramwell VW, Christensen D, Agger EM, Andersen P, et al. (2010) Liposomes based on dimethyldioctadecylammonium promote a depot effect and enhance immunogenicity of soluble antigen. J Control Rel 142: 180-186.
18. Davidsen J, Rosenkrands I, Christensen D, Vangala A, Kirby D, et al. (2005) Characterization of cationic liposomes based on dimethyldioctadecylammonium and synthetic cord factor from M. tuberculosis (trehalose 6,69-dibehenate) - a novel adjuvant inducing both strong CMI and antibody responses. Biochim Biophys Acta 1718: 22-31.
19. Weinrich Olsen A, van Pinxteren LA, Meng Okkels L, Birk Rasmussen P, Andersen P (2001) Protection of mice with a tuberculosis subunit vaccine based on a fusion protein of antigen 85b and esat-6. Infect Immun 69: 2773-2778.
20. Andersen P, Askgaard D, Ljungqvist L, Bentzon MW, Heron I (1991) T-cell proliferative response to antigens secreted by Mycobacterium tuberculosis. Infect Immun 59: 1558-1563.
21. Rosenkrands I, Agger EM, Olsen AW, Korsholm KS, Andersen CS, et al. (2005) Cationic liposomes containing mycobacterial lipids: a new powerful Th1 adjuvant system. Infect Immun 73: 5817-5826.